Aequus Historical Balance Sheet
AQS Stock | CAD 0.01 0.00 0.00% |
Trend analysis of Aequus Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 5 M, Net Tangible Assets of 1.7 M or Property Plant And Equipment Net of 683.1 K provides information on Aequus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Aequus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Aequus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Aequus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aequus Pharmaceuticals is a good buy for the upcoming year.
Aequus Pharmaceuticals Inventory |
|
Aequus |
About Aequus Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Aequus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Aequus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aequus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aequus currently owns. An asset can also be divided into two categories, current and non-current.
Aequus Pharmaceuticals Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Aequus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aequus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Aequus Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aequus Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Accounts Payable
An accounting item on the balance sheet that represents Aequus Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Aequus Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Most accounts from Aequus Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aequus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aequus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Aequus Pharmaceuticals' Property Plant Equipment is fairly stable compared to the past year. Non Current Liabilities Total is likely to climb to about 774.1 K in 2024, despite the fact that Total Stockholder Equity is likely to grow to (4.1 M).
2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 2.5M | 2.4M | 4.8M | 5.0M | Total Assets | 4.3M | 1.7M | 1.1M | 1.0M |
Aequus Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Aequus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aequus Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.7M | 3.1M | 4.3M | 1.7M | 1.1M | 1.0M | |
Total Current Liabilities | 476.0K | 384.3K | 2.5M | 2.4M | 4.8M | 5.0M | |
Total Stockholder Equity | (877.1K) | 574.0K | 1.8M | (1.4M) | (4.3M) | (4.1M) | |
Net Tangible Assets | 934.2K | (961.9K) | 574.0K | 1.8M | 1.6M | 1.7M | |
Property Plant And Equipment Net | 480.1K | 366.3K | 242.3K | 788.8K | 650.6K | 683.1K | |
Net Debt | 1.7M | 604.7K | (211.3K) | 533.1K | 4.9M | 5.1M | |
Retained Earnings | (23.7M) | (24.7M) | (26.5M) | (29.7M) | (32.7M) | (31.1M) | |
Accounts Payable | 249.5K | 160.9K | 157.1K | 88.5K | 274.2K | 286.1K | |
Cash | 484.5K | 1.7M | 2.4M | 249.8K | 170.2K | 161.7K | |
Non Current Assets Total | 564.9K | 366.3K | 755.1K | 788.8K | 650.6K | 710.7K | |
Cash And Short Term Investments | 484.5K | 1.7M | 2.4M | 294.7K | 215.0K | 204.3K | |
Net Receivables | 556.3K | 779.5K | 941.1K | 310.1K | 31.7K | 30.1K | |
Common Stock Shares Outstanding | 80.4M | 93.2M | 128.8M | 132.6M | 152.5M | 83.9M | |
Liabilities And Stockholders Equity | 1.7M | 3.1M | 4.3M | 1.7M | 1.1M | 1.0M | |
Inventory | 5.4K | 123.3K | 139.8K | 93.8K | 123.7K | 129.9K | |
Other Current Assets | 61.5K | 146.7K | 120.5K | 204.1K | 65.1K | 113.5K | |
Other Stockholder Equity | 3.7M | 4.1M | 4.3M | (1.0) | (1.15) | (1.09) | |
Total Liab | 2.5M | 2.6M | 2.6M | 3.1M | 5.4M | 5.6M | |
Total Current Assets | 1.1M | 2.8M | 3.6M | 902.7K | 435.6K | 413.8K | |
Common Stock | 18.9M | 19.1M | 21.2M | 24.0M | 27.6M | 17.2M | |
Property Plant Equipment | 14.1K | 480.1K | 366.3K | 242.3K | 278.6K | 292.6K | |
Other Current Liab | 83K | 76.3K | 221.7K | 2.2M | 42.1K | 40.0K | |
Non Currrent Assets Other | 19.0K | 761.5K | 512.8K | (1.0) | (1.15) | (1.09) | |
Non Current Liabilities Total | 2.1M | 2.2M | 102.0K | 693.8K | 583.6K | 774.1K | |
Net Invested Capital | 888.3K | 2.6M | 3.7M | 620.0K | 76.2K | 72.3K | |
Net Working Capital | 631.7K | 2.4M | 1.1M | (1.5M) | (4.4M) | (4.1M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aequus Stock Analysis
When running Aequus Pharmaceuticals' price analysis, check to measure Aequus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aequus Pharmaceuticals is operating at the current time. Most of Aequus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aequus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aequus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aequus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.